Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "First Survival Data From the NIPU Trial - Evaluating Nivo & Ipi Combined With UV1 Vaccination as 2L Treatment for Malignant Mesothelioma"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aslaug Helland
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aslaug Helland
Comments 0
Login to view comments.
Click here to Login